AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Axsome stock skyrocketed to a record high Thursday after the FDA approved Auvelity for agitation due to Alzheimer's disease.

The Food and Drug Administration (FDA) has approved Auvelity ® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer d ...

Alzheimer’s disease may begin its biological progression far earlier than symptoms suggest, with subtle shifts in brain and blood markers emerging decades in advance.

By Kamal Choudhury and Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome ...

GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...

Inhibiting an enzyme in the brain could unlock a novel way of slowing Alzheimer’s disease, a new study suggests. With ...

Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...

Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains ...

Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the ...

The idea is straightforward: Take a blood test now, even without symptoms, and learn if you could some day develop ...

Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...